Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Mantle Cell Lymphoma Previously Treated with Ibrutinib (CITADEL-205)

被引：10
|
作者：
Zinzani, Pier Luigi
Delwail, Vincent
Paneesha, Shankara
Rule, Simon
Garcia-Sancho, Alejandro Martin
Marin-Niebla, Ana
Salles, Gilles
Sancho, Juan-Manuel
Vergote, Vibeke
Zilioli, Vittorio Ruggero
Zheng, Fred
DeMarini, Douglas J.
Jiang, Wei
Mehta, Amitkumar
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-134609
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：4
相关论文
共 50 条
  • [41] FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia
    de Claro, R. Angelo
    McGinn, Karen M.
    Verdun, Nicole
    Lee, Shwu-Luan
    Chiu, Haw-Jyh
    Saber, Haleh
    Brower, Margaret E.
    Chang, C. J. George
    Pfuma, Elimika
    Habtemariam, Bahru
    Bullock, Julie
    Wang, Yun
    Nie, Lei
    Chen, Xiao-Hong
    Lu, Donghao
    Al-Hakim, Ali
    Kane, Robert C.
    Kaminskas, Edvardas
    Justice, Robert
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3586 - 3590
  • [42] ZUMA-2: Phase 2 multicenter study evaluating efficacy of kte-C19 in patients with relapsed/refractory mantle cell lymphoma.
    Wang, Michael
    Locke, Frederick Lundry
    Munoz, Javier
    Goy, Andre
    Holmes, Houston Eccleston
    Siddiqi, Tanya
    Flinn, Ian
    McSweeney, Peter A.
    Reagan, Patrick Michael
    Hill, Brian Thomas
    Jacobson, Caron A.
    Rizzieri, David A.
    Heffner, Leonard T.
    Jaglowski, Samantha Mary
    Miklos, David Bernard
    Shaughnessy, Paul
    Unabia, Sherry
    Rossi, John M.
    Jiang, Yizhou
    Jain, Rajul K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [43] A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
    Cohen, Jonathon B.
    Portell, Craig A.
    Hamadani, Mehdi
    Jegede, Opeyemi
    Diefenbach, Catherine
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Kahl, Brad S.
    BLOOD, 2019, 134
  • [44] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
    Baggio, Diva
    Wellard, Cameron
    Chung, Eliza
    Talaulikar, Dipti
    Keane, Colm
    Opat, Stephen
    Giri, Pratyush
    Minson, Adrian
    Cheah, Chan Yoon
    Armytage, Tasman
    Lee, Denise
    Chong, Geoffrey
    Johnston, Anna
    Cochrane, Tara
    Waters, Neil
    Hamad, Nada
    Wood, Erica M.
    Hawkes, Eliza A.
    LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
  • [45] Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma
    Kim, Austin I.
    Armand, Philippe
    Redd, Robert A.
    Forsyth, Megan
    Branch, Paul
    Pazienza, Samantha
    Brennan, Lisa
    Patterson, Victoria
    Waisgerber, Susan M.
    Merryman, Reid W.
    Fisher, David C.
    Ryan, Christine E.
    Ahn, Inhye E.
    Crombie, Jennifer L.
    Odejide, Oreofe O.
    LaCasce, Ann
    Jacobson, Caron A.
    Jacobsen, Eric
    Parry, Erin M.
    Davids, Matthew S.
    Brown, Jennifer R.
    Freedman, Arnold S.
    Riedell, Peter A.
    Murakami, Mark Alan
    BLOOD, 2023, 142
  • [46] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Myron S. Czuczman
    A. Goy
    D. Lamonica
    D. A. Graf
    M. C. Munteanu
    R. H. van der Jagt
    Annals of Hematology, 2015, 94 : 2025 - 2032
  • [47] Phase II study of bendamustine combined with rituximab in relapsed/refractory mantle cell lymphoma: efficacy, tolerability, and safety findings
    Czuczman, Myron S.
    Goy, A.
    Lamonica, D.
    Graf, D. A.
    Munteanu, M. C.
    van der Jagt, R. H.
    ANNALS OF HEMATOLOGY, 2015, 94 (12) : 2025 - 2032
  • [48] MATCHING-ADJUSTED INDIRECT COMPARISON OF EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS IBRUTINIB IN THE TREATMENT OF RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
    Telford, C.
    Kabadi, S.
    Abhyankar, S.
    Song, J.
    Signorovitch, J.
    Zhao, J.
    Yao, Z.
    VALUE IN HEALTH, 2019, 22 : S62 - S62
  • [49] EFFICACY AND SAFETY OF IBRUTINIB THERAPY IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA IN REAL-LIFE A MULTICENTRIC STUDY (REP - APULIAN HEMATOLOGY NETWORK)
    Gagliardi, V. P.
    Cascavilla, N.
    Di Renzo, N.
    Melpignano, A.
    Loseto, G.
    Pavone, V.
    Gaudio, F.
    Specchia, G.
    Perrone, T.
    HAEMATOLOGICA, 2017, 102 : 693 - 693
  • [50] REAL-WORLD TREATMENT OUTCOMES AMONG RELAPSED/REFRACTORY PATIENTS WITH MANTLE CELL LYMPHOMA TREATED WITH IBRUTINIB OR ACALABRUTINIB
    Crawford, S.
    Lafeuille, M. H.
    Emond, B.
    Harb, D.
    Voladarsky, R.
    Chen, N.
    Karve, S.
    VALUE IN HEALTH, 2023, 26 (06) : S403 - S403
12345